EMA gives green light to Actelion's Uptravi after safety review

ZURICH (Reuters) - The European Medicines Agency on Friday gave its green light for doctors to continue using Actelion's Uptravi, saying a review after five patient deaths in France did not suggest an increase in mortality linked to the pulmonary arterial hypertension drug.